ClinicaliQ Trial Snapshot
- Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa — Recruiting • Phase IV • NCT06940830.
- This study tracks how well efanesoctocog alfa prevents joint bleeds in haemophilia A patients receiving routine preventive treatment over the long term.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting. Conditions: Hemophilia A Interventions: Efanesoctocog alfa Lead Sponsor: Swedish Orphan Biovitrum Planned Enrollment: 250 participants